X

Vous n'êtes pas connecté

Maroc Maroc - DRUGS.COM - Pharma Industry News - 11/12/2024 15:12

Durable Response High With Obe-Cel in B-Cell Acute Lymphoblastic Leukemia

WEDNESDAY, Dec. 11, 2024 -- For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, results in a high...

Articles similaires

Sorry! Image not available at this time

Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma

drugs.com - 09/Jan 17:06

THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high...

Sorry! Image not available at this time

Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma

drugs.com - 09/Jan 17:06

THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high...

Sorry! Image not available at this time

GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer

zacks.com - 07/Jan 16:39

The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.

Sorry! Image not available at this time

Hemogenyx Pharma opens first clinical site for its lead asset, HG─CT─1, targeting R/R acute myeloid leukaemia in adults

pharmabiz.com - 31/12/2024 10:54

Hemogenyx Pharmaceuticals plc, a publicly traded company headquartered in London, announced the opening of the first clinical site for its lead asset,...

Sorry! Image not available at this time

PSMA-PET Provides Additional Risk Stratification in High-Risk Prostate Cancer

drugs.com - 09/Jan 17:01

THURSDAY, Jan. 9, 2025 -- Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging,...

Sorry! Image not available at this time

PSMA-PET Provides Additional Risk Stratification in High-Risk Prostate Cancer

drugs.com - 09/Jan 17:01

THURSDAY, Jan. 9, 2025 -- Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging,...

Sorry! Image not available at this time

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, Receives US FDA Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

drugs.com - 07/Jan 22:01

London, UK January 07 2025 -- GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Sorry! Image not available at this time

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, Receives US FDA Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

drugs.com - 07/Jan 22:01

London, UK January 07 2025 -- GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Do GLP-1 receptor agonists increase the risk of suicide in patients?

news.medical.net - 06/Jan 09:20

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal behaviors in high-risk...

How Medicare Advantage Impacts Cancer Drug Costs for Patients

medindia.net - 11/Jan 19:36

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through...